Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.

J Hematol Oncol 17(1):98 October 20, 2024

Authors: Marion Alcantara, Marion Chevrier, Fabrice Jardin, Anna Schmitt, Caroline Houillier, Lucie Oberic, Olivier Chinot, Franck Morschhauser, Frédéric Peyrade, Roch Houot, Khê Hoang-Xuan, Hervé Ghesquieres, Carole Soussain

Affiliations

CellAction, Center for Cancer Immunotherapy, Institut Curie, Suresnes, France.
Clinical Hematology Unit, Institut Curie, Saint-Cloud, 92210, France.
Department of Biostatistics, Institut Curie, Saint-Cloud, 92210, France.
Department of Clinical Hematology and INSERM U1245, Centre Henri Becquerel, Rouen, France.
Service d'Hématologie, Institut Bergonié, Bordeaux, France.
Neurooncology Department, Assistance Publique - Hôpitaux de Paris (APHP), Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Hematology, Institut Universitaire du Cancer de Toulouse Oncopôle, Toulouse, France.
AP-HM, Service de Neuro-Oncologie, CHU de la Timone, Aix-Marseille Université, CNRS, INP, Marseille Cedex, France.
Univ. Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, F-59000, France.
Service d'Onco-hématologie, Centre Hospitalier Simone Veil, Cannes, France.
Department of Hematology, University Hospital of Rennes, UMR U1236, INSERM, University of Rennes, French Blood Establishment, Rennes, France.
Department of Hematology, Hôpital Lyon Sud, Claude Bernard Lyon 1 University, Pierre- Bénite, France.
Clinical Hematology Unit, Institut Curie, Saint-Cloud, 92210, France.
Center for Cancer Immunotherapy, Institut Curie, PSL Research University, INSERM U932, Paris, 75005, France.

Research Design, Lymphoma, Central Nervous System, Lenalidomide, Nervous System